Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec and Roche have extended their global medicinal chemistry agreement signed in May 2004 for a further 12 months and their medicinal chemistry collaboration in oncology, signed in October 2003, for an additional two years.
Subscribe to our email newsletter
In the global medicinal chemistry agreement a dedicated team of chemists from Evotec supports all of Roche’s European and US research sites in the design and synthesis of high quality compounds for lead finding and optimization programs.
In the medicinal chemistry oncology collaboration, both companies aim to identify and develop a clinical lead candidate for a priority target within Roche’s oncology research.
“These significant research programs announced today are of particular importance for Evotec. They emphasize our world leading expertise in medicinal chemistry and the continued trust of our partner Roche. We look forward to continuing to work closely with scientists at Roche for a number of years,” said Dr Mark Ashton, executive vice president of business development services at Evotec.